Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2018 16:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases

IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced new preclinical data...
April 11, 2018 16:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome

Bardoxolone Treatment Produced Significant Increase in Kidney Function Maintained Through Week 36 Conference Call With Management Scheduled Thursday, April 12th at 8:30am ET IRVING, Texas, April ...
April 03, 2018 07:30 ET | Source: Reata Pharmaceuticals, Inc.

Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference

Novel, Orally-Bioavailable Agent With Potent Activity in Cell-Based and Animal Models Non-Human Primate Proof-of-Concept for Suppression of IL-17A Achieved Phase 1 Initiation for RTA 1701...
March 29, 2018 16:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan

IRVING, Texas, March 29, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa...
March 22, 2018 07:30 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial

Significant Improvement in 6MWD in Patients With IPF and Sarcoidosis No Safety Signals Identified IRVING, Texas, March 22, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA)...
March 16, 2018 16:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference

IRVING, Texas, March 16, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced that Chief Development...
March 02, 2018 07:30 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2017 Financial and Operating Results

ADVANCED TWO PROGRAMS INTO PIVOTAL TRIALS IN 2017 CARDINAL PHASE 2 RETAINED BENEFIT DATA EXPECTED 3Q18 DATA FROM FIRST PHOENIX COHORT EXPECTED 2H18 IRVING, Texas, March 02, 2018 (GLOBE NEWSWIRE)...
March 01, 2018 17:14 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies

IRVING, Texas, March 01, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced top-line data from the...
February 27, 2018 16:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials

First patient enrolled for all cohorts of PHOENIX First data from PHOENIX expected 2H18 Retained benefit analysis from Phase 2 portion of CARDINAL expected 3Q18 IRVING, Texas, Feb. 27, 2018 ...
February 12, 2018 16:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial

Progressive loss of kidney function is a validated independent predictor of death and hospitalization in PAH patients Increases in eGFR from bardoxolone methyl treatment were maintained for two years...